主要研究方向（招生专业）及内容
临床医学
1、生物学
1）移植排斥免疫反应信号通路研究；
2）移植术后病人个体化免疫抑制策略研究；
3）肝胆胰外科及肝移植外科临床及基础研究；
博士生导师 教授 器官移植中心主任。
一、学习及工作经历
l1987年--2000年，汉诺威医学院，历任外科学讲师、副教授；
l2000年--2004年，汉诺威医学院，外科学教授；
l2004年--2007年，加拿大Dalhousie大学，教授；
l2007年--2016年，汉堡大学，普通外科、血管外科、器官移植外科主任；
l2017年至今，中国科学技术大学附一院，肝肾胰移植中心主任。
二、学术成果及影响
此前担任德国汉堡大学附属医院肝胆胰外科、肝肾胰移植中心主任以及德国移植协会主席，现为美国外科学院院士、加拿大皇家外科学院院士，在包括 NEJM、Lancet等在内的国际权威杂志上发表论文百余篇，促进了相关学科的发展。
三、在研项目(仅限于主要负责人)
项目名称、来源、经费指标卡号 | 总经费(万元) | 起止日期 |
Elevate, CRAD001A2429: A 24-month, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion. |
| 2012 – ongoing |
ACTICCA Trial：Adjuvant chemotherapy with gemcitabine and cisplatine compareid to observation after curative intent resection of cholangiocarcinoma – A randomized, controlled, multidisciplinary AIO/DGAV/DGVS phase III trial, Sponsor: Deutsche Krebshilfe |
| 2013 – ongoing |
CRAD001H2307: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants. |
| 2013 – ongoing |
中国科大“新医学”创新团队基金：机械灌注下器官维护和修复多学科器官移植团队 |
| 2019 – ongoing |
四、代表性论文（近五年）
1. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Kidney Int. 2019 Jul;96(1):231-244. Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group.
2. Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. Can J Gastroenterol Hepatol. 2019 Mar 5;2019:8747438. Herden U, Schoening W, Pratschke J, Manekeller S, Paul A, Linke R, Lorf T, Lehner F, Braun F, Stippel DL, Sucher R, Schmidt H, Strassburg CP, Guba M, van Rosmalen M, Rogiers X, Samuel U, Schön GM, Nashan B.
3. Segment 5 parenchymal sparing in extended left hepatectomy with respect to venous outflow-is it a feasible procedure?
Langenbecks Arch Surg. 2018 Aug;403(5):663-670. Li J, Mohamed M, Fischer L, Nashan B.
4. Dual antibody induction and de novo use of everolimus enable low-dose tacrolimus with early corticosteroid withdrawal in simultaneous pancreas-kidney transplantation. Transpl Immunol. 2018 Oct;50:26-33. Li J, Koch M, Kramer K, Kloth K, Abu Ganim AR, Scheidat S, Rinninger F, Thaiss F, Gulati A, Herden U, Achilles E, Fischer L, Nashan B.
5. Outcome following right-extended split liver transplantation in the recent transplant era: Single-center analysis of a German transplant center. Clin Transplant. 2018 Jul;32(7):e13288. Herden U, Fischer L, Koch M, Li J, Achilles EG, Nashan B.
6. Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation. Hum Immunol. 2018 Jul;79(7):545-549. Koch M, Marget M, Sterneck M, Fischer L, Thude H, Nashan B.
7. Long-term follow-up after full-split liver transplantation and its applicability in the recent transplant era. Clin Transplant. 2018 Mar;32(3):e13205. Herden U, Fischer L, Sterneck M, Grabhorn E, Nashan B.
8. mTOR Inhibition and Clinical Transplantation: Liver. Transplantation. 2018 Feb;102(2S Suppl 1):S19-S26. Nashan B.
9. Transplantation in Germany. Transplantation. 2017 Feb;101(2):213-218. Nashan B, Hugo C, Strassburg CP, Arbogast H, Rahmel A, Lilie H.
10. Prediction, prevention, and management of delayed graft function: where are we now? Clin Transplant. 2016 Oct;30(10):1198-1208. Nashan B, Abbud-Filho M, Citterio F.
五、联系方式
E-mail: nashan@ustc.edu.cn
电话：18255110080